Qidong Gaitianli Medicines Co., Ltd Report issue

For profit Phase 3 Phase 4
Founded: Huilong China (1975)
Status: No NME R&D (1975)

Organization Overview

First Clinical Trial
2011
NCT01770431
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

huaier (5 trials)

huaiqihuang (1 trial)

Drugs in Phase 3 Trials (3)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 4)

Colorectal Neoplasms (Phase 3)

Disease Progression (Phase 4)

Neoplasm Metastasis (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Recurrence (Phase 4)

Thrombocytopenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 5